<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386607</url>
  </required_header>
  <id_info>
    <org_study_id>CSPV100A2301</org_study_id>
    <secondary_id>CSPV100A2301E1</secondary_id>
    <nct_id>NCT00386607</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.</brief_title>
  <official_title>A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg /Valsartan 320 mg in Patients With Essential Hypertension Followed by a 26 Week Open-label Extension to Assess the Long-term Safety and Tolerability of the Triple Combination of Aliskiren/Valsartan/Hydrochlorothiazide(HCTZ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Assessment of the long-term safety and tolerability of the combination of aliskiren and
      valsartan (300 mg/ 320 mg) in patients with high blood pressure,followed by assessment of
      long-term safety and tolerability of the combination of
      aliskiren/valsartan/Hydrochlorothiazide(HCTZ).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Percentage of Patients With Adverse Events</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Percentage of Patients With Adverse Events</measure>
    <time_frame>Month 18</time_frame>
    <description>adverse event data obtained from both the core study and the 6 month extension study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure.</measure>
    <time_frame>Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure.</measure>
    <time_frame>Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41 and 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Blood Pressure Control Target of &lt; 140/90 mmHg</measure>
    <time_frame>.Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure</measure>
    <time_frame>Baseline and Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure</measure>
    <time_frame>Baseline and Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Blood Pressure Control Target of &lt; 140/90 mmHg in Extension Treatment</measure>
    <time_frame>Month 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">601</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Core Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combination for 52-weeks, optional addition of Hydrochlorothiazide (HCTZ) 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (mean sitting Systolic Blood Pressure ≥ 140 and/or mean sitting Diastolic Blood Pressure ≥ 90 mmHg). The dose of Hydrochlorothiazide (HCTZ) 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients entering into extension, those previously treated with Hydrochlorothiazide (HCTZ) 12.5 or 25 mg in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension. Those patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg.
The HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the mean sitting Systolic Blood Pressure (msSBP) was ≥140 mmHg and/or the mean sitting Diastolic Blood Pressure (msDBP) was ≥90 mmHg for 2 consecutive visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 300 mg</description>
    <arm_group_label>Core Treatment</arm_group_label>
    <arm_group_label>Extension Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan 320 mg</description>
    <arm_group_label>Core Treatment</arm_group_label>
    <arm_group_label>Extension Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide (HCTZ)</intervention_name>
    <description>Hydrochlorothiazide (HCTZ) 12.5-25 mg</description>
    <arm_group_label>Extension Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: -

          -  Male and female outpatients 18 years of age and older.

          -  For newly diagnosed/untreated patients with essential hypertension defined as msDBP ≥
             90 and &lt; 110 mmHg at Visit 1 and Visit 4

          -  For previously treated patients with essential hypertension defined as msDBP ≥ 90 and
             &lt; 110 mmHg after 2 to 4 weeks of washout (Visit 4)

          -  Patients who were eligible and able to participate in the study and who consented to
             do so after the purpose and nature of the investigation had been clearly explained to
             them (written informed consent).

        Exclusion Criteria:

          -  Severe hypertension (msDBP ≥ 110 mmHg and/or msSBP ≥ 180 mmHg)

          -  Women of child-bearing potential, unless they met definition of post-menopausal or
             were using acceptable methods of contraception.

          -  History or evidence of a secondary form of hypertension.

          -  History of hypertensive encephalopathy or cerebrovascular accident.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Centers</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Centers</name>
      <address>
        <city>Canada</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Centers</name>
      <address>
        <city>Germany</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Centers</name>
      <address>
        <city>Netherlands</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <results_first_submitted>December 20, 2010</results_first_submitted>
  <results_first_submitted_qc>April 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2011</results_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Hypertension, aliskiren, valsartan, HCTZ, blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Core Treatment</title>
          <description>Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP ≥ 140 and/or msDBP ≥ 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.</description>
        </group>
        <group group_id="P2">
          <title>Extension Treatment</title>
          <description>For patients entering into extension, those previously treated with HCTZ (12.5 or 25 mg) in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension.
Those patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg.
The HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the msSBP was ≥140 mmHg and/or the msDBP was ≥90 mmHg for 2 consecutive visits.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="601"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="486"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Core Treatment</title>
          <description>Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP ≥ 140 and/or msDBP ≥ 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="601"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Percentage of Patients With Adverse Events</title>
        <time_frame>Month 12</time_frame>
        <population>Treated population: All patients who received at least one dose of Aliskiren/Valsartan</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment- Aliskiren/Valsartan &amp; Aliskiren/Valsartan/HCTZ</title>
            <description>Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP ≥ 140 and/or msDBP ≥ 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Percentage of Patients With Adverse Events</title>
          <population>Treated population: All patients who received at least one dose of Aliskiren/Valsartan</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure.</title>
        <time_frame>Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54</time_frame>
        <population>Treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment</title>
            <description>Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP ≥ 140 and/or msDBP ≥ 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure.</title>
          <population>Treated population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (Visit 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Visit 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Visit 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (Visit 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (Visit 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" spread="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 (Visit 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.0" spread="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (Visit 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.2" spread="7.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 41 (Visit 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.2" spread="7.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (Visit 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.2" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (value at week 54 or LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.4" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure.</title>
        <time_frame>Baseline and Weeks 2, 4, 6, 10, 14, 18, 28, 41 and 54</time_frame>
        <population>Treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment</title>
            <description>Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP ≥ 140 and/or msDBP ≥ 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure.</title>
          <population>Treated population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (Visit 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="12.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Visit 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.0" spread="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Visit 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.6" spread="14.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (Visit 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.4" spread="14.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (Visit 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="13.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 (Visit 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.6" spread="14.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (Visit 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.3" spread="13.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 41 (Visit 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.3" spread="13.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (Visit 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.3" spread="14.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (value at week 54 or LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" spread="16.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Blood Pressure Control Target of &lt; 140/90 mmHg</title>
        <time_frame>.Weeks 2, 4, 6, 10, 14, 18, 28, 41, and 54</time_frame>
        <population>Treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Core Treatment</title>
            <description>Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combiniation for 52-weeks, optional addition of HCTZ 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (msSBP ≥ 140 and/or msDBP ≥ 90 mmHg). The dose of HCTZ 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Blood Pressure Control Target of &lt; 140/90 mmHg</title>
          <population>Treated population</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (Visit 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Visit 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Visit 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (Visit 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (Visit 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 (Visit 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (Visit 11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 41 (Visit 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 (Visit 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (value at week 54 or LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure</title>
        <time_frame>Baseline and Month 18</time_frame>
        <population>Treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Treatment</title>
            <description>All patients receiving aliskiren / valsartan / HCTZ in extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure</title>
          <population>Treated population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Percentage of Patients With Adverse Events</title>
        <description>adverse event data obtained from both the core study and the 6 month extension study.</description>
        <time_frame>Month 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Core and Extension Treatment - Aliskiren/Valsartan/HCTZ</title>
            <description>All patients receiving aliskiren / valsartan / HCTZ during either core or extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Percentage of Patients With Adverse Events</title>
          <description>adverse event data obtained from both the core study and the 6 month extension study.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure</title>
        <time_frame>Baseline and Month 18</time_frame>
        <population>Treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Treatment</title>
            <description>All patients receiving aliskiren / valsartan / HCTZ in extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure</title>
          <population>Treated population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.8" spread="14.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Blood Pressure Control Target of &lt; 140/90 mmHg in Extension Treatment</title>
        <time_frame>Month 18</time_frame>
        <population>Treated population</population>
        <group_list>
          <group group_id="O1">
            <title>Extension Treatment</title>
            <description>All patients receiving aliskiren / valsartan / HCTZ in extension study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Blood Pressure Control Target of &lt; 140/90 mmHg in Extension Treatment</title>
          <population>Treated population</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <desc>All patients who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Core Period: Aliskiren 150 mg / Valsartan 160 mg Alone</title>
          <description>Core Period: Aliskiren 150 mg /Valsartan 160 mg alone</description>
        </group>
        <group group_id="E2">
          <title>Core Period: Aliskiren 300 mg / Valsartan 320 mg Alone</title>
          <description>Core Period: Aliskiren 300 mg /Valsartan 320 mg alone</description>
        </group>
        <group group_id="E3">
          <title>Core Period: Aliskiren / Valsartan</title>
          <description>Core Period: Aliskiren/Valsartan</description>
        </group>
        <group group_id="E4">
          <title>Core and Extension: Aliskiren / Valsartan / HCTZ 12.5 mg</title>
          <description>Core and Extension: Aliskiren / Valsartan / HCTZ 12.5 mg</description>
        </group>
        <group group_id="E5">
          <title>Core and Extension: Aliskiren / Valsartan / HCTZ 25 mg</title>
          <description>Core and Extension: Aliskiren/Valsartan/HCTZ 25 mg</description>
        </group>
        <group group_id="E6">
          <title>Core and Extension: Total</title>
          <description>Core and Extension: Total includes all study patients, treated with Aliskiren/Valsartan or Aliskiren//valsartan/HCTZ during core or extension.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal vascular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="215" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="251" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="42" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="54" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="61" subjects_at_risk="601"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="50" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="601"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="585"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="601"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="306"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open label study with no comparator treatment/arm.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

